Stoke Therapeutics (STOK) Depreciation & Amortization (CF) (2018 - 2026)
Stoke Therapeutics' quarterly Depreciation & Amortization (CF) came in at $439000.0 in Q1 2026, down 7.97% year-on-year from $477000.0 in Q1 2025, and up 8.4% quarter-over-quarter from $405000.0 in Q4 2025.
Stoke Therapeutics has reported Depreciation & Amortization (CF) for 9 years, with the latest figure at $439000.0 in Q1 2026.
- For the quarter ending Q1 2026, Depreciation & Amortization (CF) fell 7.97% year-over-year to $439000.0; the trailing twelve-month figure through Mar 2026 stood at $1.7 million (down 18.07% YoY), and the FY2025 full-year result was $1.8 million, down 19.55% from the prior year.
- Depreciation & Amortization (CF) for Q1 2026 stood at $439000.0, up from $405000.0 in the prior quarter.
- The five-year high for Depreciation & Amortization (CF) was $637000.0 in Q3 2023, with the low at $247000.0 in Q1 2022.
- Average Depreciation & Amortization (CF) over 5 years is $495529.4, with a median of $540000.0 recorded in 2024.
- Year-over-year, Depreciation & Amortization (CF) surged 141.7% in 2023 and declined 26.23% in 2025.
- Tracing STOK's Depreciation & Amortization (CF) over 5 years: stood at $609000.0 in 2022, then grew by 2.46% to $624000.0 in 2023, then decreased by 12.02% to $549000.0 in 2024, then decreased by 26.23% to $405000.0 in 2025, then increased by 8.4% to $439000.0 in 2026.
- The last three Depreciation & Amortization (CF) figures came in at $439000.0 (Q1 2026), $405000.0 (Q4 2025), and $442000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 1,395.22 |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 55.90 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 123.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 13.55 Mn |
| 10 | Stoke Therapeutics | 1.92 Bn | 1.92 Bn | - | 439,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 439,000.00 |
| Mar 31, 2026 | 439,000.00 |
| Dec 31, 2025 | 405,000.00 |
| Dec 31, 2025 | 405,000.00 |
| Sep 30, 2025 | 442,000.00 |
| Sep 30, 2025 | 442,000.00 |
| Jun 30, 2025 | 446,000.00 |
| Jun 30, 2025 | 446,000.00 |
| Mar 31, 2025 | 477,000.00 |
| Mar 31, 2025 | 477,000.00 |
| Dec 31, 2024 | 549,000.00 |
| Dec 31, 2024 | 549,000.00 |
| Sep 30, 2024 | 540,000.00 |
| Sep 30, 2024 | 540,000.00 |
| Jun 30, 2024 | 548,000.00 |
| Jun 30, 2024 | 548,000.00 |
| Mar 31, 2024 | 563,000.00 |
| Mar 31, 2024 | 563,000.00 |
| Dec 31, 2023 | 624,000.00 |
| Dec 31, 2023 | 624,000.00 |
| Sep 30, 2023 | 637,000.00 |
| Sep 30, 2023 | 637,000.00 |
| Jun 30, 2023 | 611,000.00 |
| Jun 30, 2023 | 611,000.00 |
| Mar 31, 2023 | 597,000.00 |
| Mar 31, 2023 | 597,000.00 |
| Dec 31, 2022 | 609,000.00 |
| Dec 31, 2022 | 609,000.00 |
| Sep 30, 2022 | 388,000.00 |
| Sep 30, 2022 | 388,000.00 |
| Jun 30, 2022 | 302,000.00 |
| Jun 30, 2022 | 302,000.00 |
| Mar 31, 2022 | 247,000.00 |
| Mar 31, 2022 | 247,000.00 |
| Dec 31, 2021 | 261,000.00 |
| Dec 31, 2021 | 261,000.00 |
| Sep 30, 2021 | 254,000.00 |
| Sep 30, 2021 | 254,000.00 |
| Jun 30, 2021 | 249,000.00 |
| Jun 30, 2021 | 249,000.00 |
| Mar 31, 2021 | 236,000.00 |
| Mar 31, 2021 | 236,000.00 |
| Dec 31, 2020 | 249,000.00 |
| Dec 31, 2020 | 249,000.00 |
| Sep 30, 2020 | 234,000.00 |
| Sep 30, 2020 | 234,000.00 |
| Jun 30, 2020 | 224,000.00 |
| Jun 30, 2020 | 224,000.00 |
| Mar 31, 2020 | 193,000.00 |
| Mar 31, 2020 | 193,000.00 |
| Dec 31, 2019 | 139,000.00 |
| Dec 31, 2019 | 139,000.00 |
| Sep 30, 2019 | 126,000.00 |
| Sep 30, 2019 | 126,000.00 |
| Jun 30, 2019 | 105,000.00 |
| Jun 30, 2019 | 105,000.00 |
| Mar 31, 2019 | 80,000.00 |
| Mar 31, 2019 | 80,000.00 |
| Dec 31, 2018 | 75,000.00 |
| Dec 31, 2018 | 75,000.00 |
| Sep 30, 2018 | 64,000.00 |
| Sep 30, 2018 | 64,000.00 |